new and emerging therapies in hcv
Introducing SeamlessCME™ INTERACTIVE CME-CERTIFIED DINNER SYMPOSIUM Strategies for Safe and Efficacious Use of 2.0 A technology platform in which participants will utilize provided iPads to log into the event, respond to assessment and evaluationn questions, view all slides, and interact with the faculty. NEW AND EMERGING DAA THERAPIES IN HCV Monday, May 18, 2015 Marriott Marquis Washington, DC Marquis Ballroom – Salon 6 Level 2 6:00 pm – 6:30 pm Registration and Dinner oral HCV G1 cirrhosis tx-naï aïve interferon- SVR ACTIVITY CHAIR Ira Jacobson, MD HCV SVR FACULTY Andrew Muir, MD, MHS Nancy Reau, MD Mark Sulkowski, MD 6:30 pm – 8:30 pm CME-certified Activity This continuing medical education activity is provided by VINDICO medical education This activity is supported by an educational grant from Gilead Sciences Medical Affairs ® This program is not affiliated with Digestive Disease Week . REGISTER ONLINE! VindicoCME.com/051815 DA DAA 2015 © iStockphoto.com/Ballun; caracterdesign OV VERVIEW W DAA DA AA Chronic hepaatitis C viru us (HCV) infection iss a leaading causse of cirrhoosis, end-sstage liverr disease, hepatocellular carcinom ma, and death from liver diseaase in the United Statess. The disccovery, deevelopmennt, and availability of direct-actiing antiviraal agents (DAAs) offfers new treeatment opttions and the possibility of im mproved outtcomes forr newly diaagnosed paatients as well as thhose who have experiienced a relapse or faailed to respond to previous tre eatment. With the approval of all-oral, intterferon-free combination therrapies forr HCV treattment, heaalth care professionaals continuue to be challengeed by severral clinica al questions. In this CME acttivity, strattegies for the safe and efficaciious use off HCV theerapies, allong with thhe importtance of acchieving su ustained viral responsse for imprrovement of hepatic and extrahhepatic maanifestations in mild as well as severe disease, wiill be disscussed. The clinicall evidence e regardingg optimal treatment duration, moonitoring sttrategies, and drug--drug interaactions forr interferonn-free regim mens willl be review wed, along with theeir use in unique patiient populations. LEARNING OBJECTIVES Upon successful completion of this educational activity, participants should be better able to: • Discuss the importance of HCV treatment and achievement of sustained viral response for improvement of hepatic and extrahepatic manifestations, in mild as well as severe disease. • Apply the clinical evidence to optimize treatment duration, monitoring strategies and drug-drug interactions for newly approved and emerging interferon-free regimens. • Appraise the clinical evidence to determine how to optimize the use of newly approved and emerging interferon-free regimens in special populations of patients including those with decompensated cirrhosis, HIV/HCV coinfection, transplant/ post-transplant of liver, renal Impairment, and HCV genotype 3. TARGET AUDIENCE The intended audience for the activity is gastroenterologists, hepatologists, nurse practitioner and physician assistant HCV specialists, and other health care professionals involved in the treatment of patients with HCV. REGISTER ONLINE! VindicoCME.com/051815 Introducing SeamlessCME™ AGENDA A technology platform in which participants will utilize provided iPads to log into the event, respond to assessment nt and evaluation questions, view all slides, and interact with the faculty. 6:30 pm – 6:35 pm Introduction and Pretest Ira Jacobson, MD 6:35 pm – 6:55 pm The Value Proposition of Achieving SVR: Multifaceted Benefits & Managing Resource Challenges Nancy Reau, MD 6:55 pm – 7:20 pm 7:20 pm – 7:45 pm Initial Treatment for a Patient with HCV Genotype 1: Considerations for Interferon-Free Treatment Regimens Ira Jacobson, MD Retreatment When Prior Therapy Has Failed Andrew Muir, MD, MHS 7:45 pm – 8:05 pm Key Points for the Use of New HCV Therapies in Distinct Populations Mark Sulkowski, MD HCV 8:05 pm – 8:15 pm Posttest Ira Jacobson, MD 8:15 pm – 8:30 pm Question and Answer Moderated by Ira Jacobson, MD Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours credit for completing this program. This educational activity is designed for AMA PRA Category 1 Credit(s)™ for US physicians only. All non-US physicians should contact their respective Boards for accreditation/credit status. In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience. Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee. tx-naïve REGISTER ONLINE! VindiccoCM ME.coom/00518115 SVR ACTIVITY CHAIR FACULTY Ira Jacobson, MD Andrew Muir, MD, MHS Chairman, Department of Medicine Mount Sinai Beth Israel Medical Center Vice Chair of Medicine Mount Sinai Health Care System Senior Faculty, Icahn School of Medicine at Mount Sinai New York, NY Chief, Division of Gastroenterology Director, GI/Hepatology Research Group Associate Professor of Medicine Department of Medicine Duke University Durham, NC oral HC CV Nancy Reau, MD DAA DA A G1 Associate Professor of Medicine University of Chicago Chicago, IL cirrho hosis sis tx-na txnaïve inte in nterfe rferonfree SVR SV R Mark Sulkowski, MD HCV SV VR DAA DA A Professor of Medicine Medical Director of the Viral Hepatitis Center Johns Hopkins School of Medicine Baltimore, MD REGISTER ONLINE! VindicoCME.com/051815 Monday, May 18, 2015 Marriott Marquis Washington, DC Marquis Ballroom – Salon 6 Level 2 6:00 pm – 6:30 pm Registration and Dinner 6:30 pm – 8:30 pm CME-certified Activity INTERACTIVE CME-CERTIFIED DINNER SYMPOSIUM Strategies for Safe and Efficacious Use of NEW AND EMERGING THERAPIES IN HCV First Name ______________________________ M.I._______ Last Name _________________________________________ Preferred Mailing Address (Home/Business) ___________________________________________________________________ ______________________________________________________________________________________________________ City___________________________ REGISTER ONLINE! VindicoCME.com/051815 2.0 State_______ Zip Code ______________ Country ____________________________ Daytime Phone_______________________________________ Evening Phone ______________________________________ Fax ____________________________ E-mail ______________________________________ Date of Birth _______________ (for confirmation purposes) (for confirmation purposes) (for tracking credits ONLY) National Provider Identifier (NPI)_______________ Medical License Number______________ Medical License State____________ Contact Information: E-mail: [email protected] Toll-free: 877-307-5225, ext. 219 or 476 Phone: 856-994-9400, ext. 219 or 476 Fax: 856-251-0278 Mail: Registration Department 6900 Grove Road Thorofare, NJ 08086-9447 Priority Code: 678 - 1 2 3 Degree (please sppecify) ❑ MD/DO ❑ PhD ❑ MD, PhD ❑ PharmD/RPh ❑ PA ❑ RN/BSN/MSN ❑ NP ❑ Industry ❑ Other:_______ Ho ow did you hear about this meetting? (mu ultiple selectio ons allowed) ❑ Advertisement ❑ Brochure ❑ E-mail ❑ Postcard ❑ Web site ❑ Word of mouth Spe ecialtty (seelect onee) ❑ ❑ ❑ ❑ Gastroenterology Hepatology Infectious Disease Surgery ❑ Internal Medicine ❑ Family Practice/ General Practice CM ME Activvity Requ uest ❑ YES, I would like to receive information regarding future CME activities related to this therapeutic area. ADA compliance: In compliance with the Americans with Disabilities Act of 1990, we will make reasonable efforts to accommodate persons with disabilities. Please call with your requests. INTERACTIVE CME-CERTIFIED DINNER SYMPOSIUM Strategies for Safe and Efficacious Use of NEW AND EMERGING THERAPIES IN HCV Monday, May 18, 2015 Marriott Marquis Washington, DC Marquis Ballroom – Salon 6 Level 2 6:00 pm – 6:30 pm Registration and Dinner 6:30 pm – 8:30 pm CME-certified Activity REGISTER ONLINE! VindicoCME.com/051815 2.0 VINDICO medical education 6900 Grove Road • Building 100 Thorofare, NJ 08086-9447 Presorted First Class Mail US Postage PAID Permit # 906 Bellmawr NJ
© Copyright 2024